USV Pvt Ltd and Biogenomics have launched INSUQUICK®, India’s first biosimilar Insulin Aspart, aimed at enhancing diabetes access for individuals. Diabetes is a growing healthcare concern in India as nearly 11.4% of the country’s adult population, which accounts for 101 million people, are living with diabetes. Besides this, there are an additional 136 million people who are pre-diabetic and who have a high propensity to convert into diabetes in a short time.
InsuQuick is a “Make in India” product, developed and manufactured using 100% indigenous technology, and has undergone a robust clinical program to ensure global quality standards. It is available in all metros, and Tier I/II cities. Dr. Sanjay Sonar, Co-Founder and President of Biogenomics, said, “Insulin aspart is the first biosimilar in the category of rapid-acting insulin and is a result of more than ten years of R&D efforts.”
USV plans to introduce Insuquick, a diabetes-specific pens with a contemporary design and legible scale, alongside Insulin Aspart, aiming to enter the insulin market with robust R&D for comprehensive diabetes solutions.
